drugset / Trial / NCT07355205
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Phase 1/2
Recruiting
26 enrolled
Washington University School of Medicine
ImmunityBio, Inc. · collabThe Foundation for Barnes-Jewish Hospital · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a single center, phase Ib/II study combining an anti-PD-1 antibody and an anti-CTLA-4 antibody with IL-15. It is testing the hypothesis that the addition of nogapendekin alfa inbakicept to nivolumab and ipilimumab will augment the clinical activity of those two drugs.
Timeline
- Start
- 2026-07-07
- Primary completion
- 2032-07-31
- Completion
- 2032-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-803 | Protein / enzyme biologic | — | Subcutaneous |
| Background | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Background | Nivolumab | Monoclonal antibody | 360 mg | Intravenous |